Guideline for Technology Transfer (Draft)
|
|
- Caren Lewis
- 6 years ago
- Views:
Transcription
1 Scientific Research Granted by the Ministry of Health, Labor and Welfare in 2003 Research on Current Quality System of Drug Products Research Report Yukio Hiyama, Chief Researcher, Division of Drugs, the National Institute of Health Sciences Guideline for Technology Transfer (Draft) Members of research group Chairperson Izumi Saitoh (Shionogi & Co., Ltd.) Kazufumi Ikeda (TANABE SEIYAKU CO., LTD.) Akio Imai (Eisai Co., Ltd.) Atsuo Oike (Fujisawa Pharmaceutical Co., Ltd.) Hiroshi Okada (Department of Health and Human Services, Saitama Prefecture) Ryoichi Kawakami (Fujisawa Pharmaceutical Co., Ltd.) Yukihiko Kimura (Chugai Pharmaceutical Co., Ltd.) Yasuyuki Sakai (Chugai Pharmaceutical Co., Ltd.) Yoshiyuki Sawabe (Osaka Prefectural Institute of Public Health) Masaaki Mikawa (Pfizer Japan Inc.) Noriyuki Muranushi (Shionogi & Co., Ltd.) Keiichiro Watanabe (JGC CORPORATION) 1
2 Introduction This research is intended to indicate appropriate guidance for technology transfer expected to increase under the new manufacturing and marketing approval system to be implemented by the revised Japanese Pharmaceutical Affairs Law, and supplement the GMP regulations to be revised soon. The research is also intended to propose some regulations to realize technology transfer necessary for high quality and stable manufacturing of developed products and existing products by reviewing technology transfer based on the following ideas. The technology transfer means actions to transfer information and technologies necessary to realize quality of design of drugs during manufacturing. Appropriate technology transfer is important to upgrade the quality of design to be the quality of product, and ensure stable and high quality of the product. It should be noted that drugs may influence human lives and health, and their raw materials, compositions and manufacturing methods are changed during their long term manufacturing and marketing. To assure the drug quality, it is desired to make sure 5 W s and 1 H, that is what, when and why information should be transferred to where and by whom and how to transfer, then share knowledge and information of the drug product between transferring and transferred parties. The technology transfer does not mean one time actions taken by the transferring party toward the transferred party, but means continuous information exchange between the both parties to maintain the product manufacturing. Basic Policies on the Establishment of the Guideline for the Technology Transfer The basic policies on the establishment of this guideline are shown as follows. 1) Assurance of consistency through development and manufacturing To make developed product have indications as assumed in clinical phases, the quality of design should be reproducible as the quality of product. The transferring party in charge of development should fully understand what kind of technical information is required for the technology transfer, and should establish an appropriate evaluation method to determine whether a drug to be manufactured meets the quality of design. It should be fully recognized that technical information of developed product are generated from data of a limited amount of batches, various standards have been established from the limited data, and quality evaluation method established in development phase is not always sufficient for factory production. Information of similar products of the past should be fully referred as well. 2) Embodiment of Quality by Specifications It is desired to verify that the specification adequately specifies the product properties and quality. The product specification should ensure that the quality assumed in the quality design is assured as the manufacturing quality, and the product satisfies the quality of design. It should be fully understood that manufacturing quality is based on the product specification. Relations between control limits of manufacturing formula (compositions and manufacturing methods) and limits of the product specification should be fully understood, and appropriate specifications and the control range should 2
3 be established to maintain the consistency between the manufacturing quality and product specification. For specifications of raw materials, components, intermediates, and in process testing, consistency between test items, specification range, and product specifications should be maintained. Since initial manufacturing formula and specification are established based on limited information, the consistency between the quality and specification after the start of manufacturing should be fully verified, and these should be revised through appropriate change controls, if necessary. 3) Documentation Management and Update of Technical Information Responsibility system should be established in view of accountability (responsibility for giving sufficient information) and responsibility (responsibility for consequences of actions). For that purpose, appropriate documentation management of technology transfer ishighly desired. For drugs as they have long product shelf life, the documentation management should be performed assuming that the technology transfer would occur several decades after the completion of development. Initial manufacturing quality is established based on limited information. As a result, it may be necessary to propose revised technical information at regular intervals as additional information of the product quality is gained and accumulated with improvements or revisions of specifications and test methods. Table of Contents The table of contents is shown as follows. The 1st chapter addresses background and the scope of the guideline. The 2nd chapter addresses handling and contents of technologies to be transferred at each process from research and development to manufacturing. The remaining chapters address procedures, documentation, and points of concern with regard to facilities, test methods, drug substances, and drug products all of which are closely involved with drug manufacturing. 1. Preface 1.1 Background 1.2 Objective 1.3 Scope 1.4 Organization 2. Technology Transfer Process 2.1 Quality Design (Research Phase) 2.2 Scale-up and Detection of Quality Variability Factors (Development Phase) Research for Factory Production Consistency between Quality and Specification Assurance of consistency through development and manufacturing 2.3 Technology Transfer from R&D to Production 2.4 Validation and Production (Production Phase) 2.5 Feedback of Information Generated from Production Phase and Technology Transfer of Marketed Products 3. Procedures and Documentation of Technology Transfer 3
4 3.1 Organization for Technology Transfer 3.2 Research and Development Report 3.3 Technology Transfer Documentation Product Specification (Product Specification File) Technology Transfer Plan Technology Transfer Report Check and Approval by Quality Assurance Department 3.4 For Implementation of Technology Transfer 3.5 Manufacturing Related Documents Including Drug Product Standards 3.6 Verification of Results of Technology Transfer 3.7 Points of Concern for Post-Marketing Technology Transfer 4. Examples of Technical Information to be Contained in Technology Transfer Documentation 4.1. Technical Information of Facilities and Equipments Technical Information to Establish New Facilities and Equipments Technical Information When Applied to Established Facilities and Equipments 4.2 Technology Transfer of Test Methods Development Report of Test Methods Technology Transfer Plan 4.3 Technology Transfer of Drug Substances Information to be Collected During Quality Design (Research Phase) Items to be Checked in the Review of Scale-up Elucidation of Quality Variability Factors Development Report on Synthetic Drug Substances Technology Transfer of Synthetic Drug Substances from R&D Department to Manufacturing Department 4.4 Technology Transfer of Drug Products Information to be Collected During Quality Design (Research Phase) Scale-up Validation and Detection of Quality Variability Factors (Development Phase) Development Report Information of Technology Transfer of Drug Products 5. Points of Concern For Preparing Technology Transfer Documentation 5.1 Documents To Clarify Applicable Technologies, Burden Shares and Responsibility System, etc. Concerning Technology Transfer 5.2 Technical information to be Described in the Development Report, and Product Specification, etc. 4
5 Acknowledgement This draft guideline is written by the members shown below. Our sincerest appreciation should be extended to many people of the pharmaceutical industry and government offices for their valuable insights and proposals during drafting this guideline and their contributions to the completion of this draft guideline in line with the actuality of the technology transfer. Izumi Saitoh Kazufumi Ikeda Akio Imai Atsuo Oike Hiroshi Okada Ryoichi Kawakami Yukihiko Kimura Yasuyuki Sakai Yoshiyuki Sawabe Masaaki Mikawa Noriyuki Muranushi Keiichiro Watanabe (Shionogi & Co., Ltd.) (TANABE SEIYAKU CO., LTD.) (Eisai Co., Ltd.) (Fujisawa Pharmaceutical Co., Ltd.) (Department of Health and Human Services, Saitama Prefecture) (Fujisawa Pharmaceutical Co., Ltd.) (Chugai Pharmaceutical Co., Ltd.) (Chugai Pharmaceutical Co., Ltd.) (Osaka Prefectural Institute of Public Health) (Pfizer Japan Inc.) (Shionogi & Co., Ltd.) (JGC CORPORATION) 5
Quality Regulation under Revised Pharmaceutical Affair Law
Quality Regulation under Revised Pharmaceutical Affair Law Yukio Hiyama, Ph.D. Division of Drugs, National Institute of Health Sciences, the Ministry of Health, Labour and Welfare, Japan E mail hiyama@nihs.go.jp
More informationGlobal GMP Harmonisation A Japanese Perspective
Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
More informationShionogi to Announce Corporate Reorganization and Personnel Reassignment
Shionogi to Announce Corporate Reorganization and Personnel Reassignment Osaka, Japan, February 28, 2018 - Shionogi & Co., Ltd. (Head : Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter Shionogi
More informationIntellectual Property Strategy Network, Inc. (IPSN) Its Concept. Dr. Hiroshi Akimoto [Objectives of the Company]
Intellectual Property Strategy Network, Inc. (IPSN) Its Concept Dr. Hiroshi Akimoto fatomoko@maia.eonet.ne.jp [Objectives of the Company] One of the objectives of this company is to make assistance to
More informationCMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
More informationRaising Quality Levels and Ensuring Product Safety
Raising Quality Levels and Ensuring Product Safety Management System Based on the management philosophy that its founder espoused that the company should strive to contribute to society through its products
More informationQUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
VICH GL 45 (QUALITY) BRACKETING AND MATRIXING April 2010 For Implementation at Step 7 QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
More informationSubmission of comments on Review of the Variations Guidelines (EC 1234/2008)
12 July 2012 Submission of comments on Review of the Variations Guidelines (EC 1234/2008) Comments from: Name of organisation or individual Leem Please note that these comments and the identity of the
More informationImportance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationClaus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
More informationFiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines
Fifth Edition Fiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines April 2007 Ministry of the Environment, Japan First Edition: June 2003 Second Edition: May 2004 Third
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationQuality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationChallenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationSumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
March 1, 2018 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in s and Other Key Positions Sumitomo Dainippon Pharma Co., Ltd. (Head Office:
More informationEnforcement Regulations of the Pharmaceutical Affairs Law
Enforcement Regulations of the Pharmaceutical Affairs Law The Enforcement Regulations of the Pharmaceutical Affairs Law ( PAL ) shall be amended, in part, as follows: Article 24 (Product approval application
More informationThe Science and Technology Basic Law (Unofficial Translation)
The Science and Technology Basic Law (Unofficial Translation) (Law No. 130 of 1995. Effective on November 15, 1995) Table of Contents Chapter 1 General Provisions (Articles 1-8) Chapter 2 Science and Technology
More information18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*)
18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*) Research Fellow: Kenta Kosaka In the pharmaceutical industry, the development of new drugs not only requires
More informationNOTICE OF THE 106TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from selected sections of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original,
More informationRequirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2 Introduction:
More informationPharmaceutical Manufacturing and Engineering Catalog Excerpt
Pharmaceutical Manufacturing and Engineering Catalog Excerpt PME 530 Introduction to Pharmaceutical Manufacturing Pharmaceutical manufacturing is vital to the success of the technical operations of a pharmaceutical
More informationAppendix-1. Project Design Matrix (PDM)
Appendix-1 Project Design Matrix (PDM) Appendix-I Project Design Matrix (PDM) Version 1 PDM: Electric Power Technical Standards Promotion Project in Vietnam Duration: 3 Years (March in 2010 to January
More informationWG food contact materials
WG food contact materials Monday 30 January European Commission DG SANTE, Unit E2 Food Processing Technologies and Novel Foods Food Contact Materials This presentation does not present any official views
More informationEngineering Drawing System
LPR 7320.1 Effective Date: July 18, 2004 Expiration Date: July 18, 2008 Langley Research Center Engineering Drawing System National Aeronautics and Space Administration Responsible Office: Systems Engineering
More informationNotice of the 46th Annual General Meeting of Shareholders
Translation Note: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More informationdoc.: IEEE d IEEE P Wireless Personal Area Networks
August, 2008 doc.: IEEE 802. 15-08-0578-00-004d IEEE P802.15 Wireless Personal Area Networks Project Title IEEE P802.15 Working Group for Wireless Personal Area Networks (WPANs) English transl ation ofarib
More informationWeather and Environmental Services - QMS Manual
1.0 SECTION ONE - INTRODUCTION 1.1 Purpose Reference.: Page 1 of 5 This process provides a new, changed or acquired off the shelf design, process, procedure, methodology or technology that addresses a
More informationCollaboration for Human Rights Due Diligence
February 20, 2014 Collaboration for Human Rights Due Diligence Human rights are one of the core CSR topics sparking discussions and various activities in recent years, including in Japan. Since September
More informationAS/NZS IEC :2013
AS/NZS IEC 61000.4.6:2013 IEC 61000-4-6, Ed. 3.0 2008, IDT Australian/New Zealand Standard Electromagnetic compatibility (EMC) Part 4.6: Testing and measurement techniques Immunity to conducted disturbances,
More informationRecent Trend of Generic Medicines Market In Japan
Recent Trend of Generic Medicines Market In Japan Joint 22 nd EGA and 19 th IGBA Annual Conference Dubrovnik, Croatia 9 June, 2016 Itsuro Yoshida President of Japan Generic Medicines Association Copyright
More informationPMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
More informationNOTICE OF THE 119TH ORDINARY GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the
More informationQuality Risk Management
Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.
More informationTGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations
TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations MTAA Response - October 2017 October 2017 Australian Regulatory Considerations Page 1 of 7 Level
More informationJapan s FinTech Vision
Japan s FinTech Vision First Comprehensive Industrial Finance Division Economic and Industrial Policy Bureau Ministry of Economy, Trade and Industry 1 FinTech: New Finance to Support the Fourth Industrial
More informationImplementation of ICH Q8 and QbD An FDA Perspective
ISPE, Yokohama, Japan June 9, 2006 Implementation of ICH Q8 and QbD An FDA Perspective Chi-wan Chen, Ph.D. Office of New Drug Quality Assessment Center for Drug Evaluation and Research Food and Drug Administration
More informationGlobal Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel
Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel mljweitzel@msn.com Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationAPI hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.
API hapis High Potency Active Pharmaceutical Ingredients High Potency Active Pharmaceutical Ingredients Innovation made. Easy. 2 High Potency Active Pharmaceutical Ingredients High potency APIs are our
More informationHealth Based Exposure Limits (HBEL) and Q&As
Health Based Exposure Limits (HBEL) and Q&As The EMA guideline (EMA/CHMP/ CVMP/ SWP/169430/2012) & EMA/CHMP/CVMP/SWP/463311/2016 Graeme McKilligan, UK, MHRA. Content Intent of HBEL Post Implementation
More informationJapan s Initiatives to Support MSMEs Activities in Standardization
2016/SOM3/SCSC/WKSP/004 Session 3 Japan s Initiatives to Support MSMEs Activities in Standardization Submitted by: Japan Workshop on Supporting MSMEs Trade Facilitation Through Standardization Activities
More informationAnnouncement of the US Business Restructuring
August 15, 2018 Shin Nippon Biomedical Laboratories, Ltd. (The First Section of the Tokyo Stock Code Number: 2395) Representative: Chairman and President Ryoichi Nagata C o n t a c t : Senior Executive
More informationthe SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
More informationAustralian/New Zealand Standard
AS/NZS 5070.2:2008 AS/NZS 5070.2:2008 Australian/New Zealand Standard Siting and operation of radiocommunications facilities Part 2: Guidelines for siting of radiocommunications facilities: VHF, UHF and
More informationEffects of the Work Improvement on Board (WIB) program for improving safety and health of seamen
Effects of the Work Improvement on Board (WIB) program for improving safety and health of seamen Shuji Hisamune a, Kazutaka Kogi b a Faculty of Economic, Takasaki City University of Economics, Takasaki,
More informationNOTICE OF THE 48TH ORDINARY GENERAL MEETING OF SHAREHOLDERS
This document has been translated from the Japanese original for the convenience of non-japanese shareholders. In the event of any discrepancy between this translation and the Japanese original, the original
More informationAustralian/New Zealand Standard
Australian/New Zealand Standard Quality management and quality assurance Vocabulary This Joint Australian/New Zealand Standard was prepared by Joint Technical Committee QR/7, Quality Terminology. It was
More informationAPI COPM CPMA Chapter 20.X
API COPM CPMA Chapter 20.X David Courtney Pamela Chacon Matt Zimmerman Dan Cutting 24 23 February 2017 Houston, TX Copyright 2017, Letton Hall Group. This paper was developed for the UPM Forum, 22 23 February
More informationICH Q-IWG Integrated Training Programme
Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer
More informationLICENCE. for WEB LINKS. Check if this document is current Find similar documents StandardsWatch (info and login) Visit our website
LICENCE for Licensee: Date: Conditions of use: Click here for full conditions of Licence WEB LINKS Check if this document is current Find similar documents StandardsWatch (info and login) Visit our website
More informationSumitomo Seika Chemicals Company, Limited
Success Story High-quality Production with the Fusion of Process Knowledge and Data Analysis Technology - Process Data Analysis Using Machine Learning - Sumitomo Seika Chemicals Company, Limited Location:
More informationFebruary 5, 2010 VIA ELECTRONIC SUBMISSION
February 5, 2010 VIA ELECTRONIC SUBMISSION Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Current Good Manufacturing Practice
More informationNOTICE TO CONVENE THE 70TH ORDINARY GENERAL SHAREHOLDERS MEETING
To Our Shareholders (FOR REFERENCE PURPOSE ONLY) Securities Code: 4528 May 31, 2018 Gyo Sagara President & CEO Ono Pharmaceutical Co., Ltd. 1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan Head Office: 8-2,
More informationQ8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
More informationConnecting People, Science and Regulation
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway Suite 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
More information(P.27)
(P.27) 27 7 210 120 8 * Navigation and Anchoring Prohibited Area has been changed since June, 2017. 9 Port of Osaka The Guidelines of Measures for preventing Typhoon Disaster ( Objective )
More informationTwo Subsidiaries of TNSC to Merge in April
February 2, 2005 Dia Reiki Kogyo Co., Ltd. Nissan Kogyo Co., Ltd. Two Subsidiaries of TNSC to Merge in April Taiyo Nippon Sanso Corporation (TNSC) hereby announces that two of its subsidiary companies
More informationNOTICE OF THE 20TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the
More informationNotice of the 62 nd Ordinary General Meeting of Shareholders
Notice of the 62 nd Ordinary General Meeting of Shareholders June 24, 2016 Kyoto, Japan 6 Takeda Tobadono-cho, Fushimi-ku, Kyoto, Japan Please note that this is an English translation of the Japanese original
More informationEngineering Drawing System
LPR 7320.1 Effective Date: February 2, 2010 Expiration Date: February 2, 2015 Langley Research Center Engineering Drawing System National Aeronautics and Space Administration Responsible Office: Systems
More informationLIGHTHOUSE. The Science of Pharmaceutical Manufacturing
The Science of Pharmaceutical Manufacturing The Power of headspace inspection insight into the process. On the other hand, rapid non-destructive headspace analysis from is a powerful analytical tool for
More informationNational Standard of the People s Republic of China
ICS 01.120 A 00 National Standard of the People s Republic of China GB/T XXXXX.1 201X Association standardization Part 1: Guidelines for good practice Click here to add logos consistent with international
More informationDevelopment of Remote Monitoring System for Operating Power Plants Using Thin-film UT Sensors
1 Development of Remote Monitoring System for Operating Power Plants Using Thin-film UT Sensors YUKO YAMAMOTO *1 KAZUUMI KONDO *2 TADASHI KIMURA *1 SEIICHI KAWANAMI *3 YUMA ITAHASHI *4 TAKESHI KODAIRA
More informationQbD Application in Japan: PMDA Perspective
CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals
More informationRecord of Discussions On Further sophistication of industrial structure as well as human resources development and R&D promotion in Thailand
Record of Discussions On Further sophistication of industrial structure as well as human resources development and R&D promotion in Thailand The Ministry of Science and Technology, The Office of the National
More informationOSIsoft. Users Conference 2013
OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationCouncil for Science, Technology and Innovation of Japan
2015/CSA/006 Agenda Item: 3 Council for Science, Technology and Innovation of Japan Purpose: Information Submitted by: Japan Third APEC Chief Science Advisors and Equivalents Meeting Kuala Lumpur, Malaysia
More informationNOTICE OF THE 89TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the
More informationNOTICE OF THE 110TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from a part of Japanese original for reference purposes only. In event of any discrepancy between this translated document and Japanese original, original shall
More informationFROM THE GLASS TUBE TO OPTIMUM SYSTEM PACKAGING
Packaging from aus tubing Röhrenglas glass isoverpackungen Precious contents perfectly packaged FROM THE GLASS TUBE TO OPTIMUM SYSTEM PACKAGING www.iso-online.de Made in Germany Contents Philosophy Production
More informationAustralian/New Zealand Standard
AS/NZS 3439.2:2002 IEC 60439-2:2000 AS/NZS 3439.2 Australian/New Zealand Standard Low-voltage switchgear and controlgear assemblies Part 2: Particular requirements for busbar trunking systems (busways)
More information(Fig.) JPMA Industry Vision 2025
2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation
More informationInternational Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT
Research Article Analytical Chemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY SARAVANA KUMAR.V
More informationThe Collaborative Digital Process Methodology achieved the half lead-time of new car development
The Collaborative Digital Process Methodology achieved the half lead-time of new car development Hiroshi Katoh (Digital Process Ltd.) Abstract A Japanese automotive manufacturer finally achieved the less
More informationAustralian Standard. Design review AS IEC IEC 61160, Ed.2 (2005) AS IEC
AS IEC 61160 2008 IEC 61160, Ed.2 (2005) AS IEC 61160 2008 Australian Standard Design review This Australian Standard was prepared by Committee QR-005, Dependability. It was approved on behalf of the Council
More informationRicoh's Machine Vision: A Window on the Future
White Paper Ricoh's Machine Vision: A Window on the Future As the range of machine vision applications continues to expand, Ricoh is providing new value propositions that integrate the optics, electronic
More informationWEB Fujitsu Customer Relations Center (in Japanese) WEB Regarding PCBs in Fujitsu Condensers (in Japanese) WEB The Quiet Server.
With Our Customers Our Basic Stance Based on the statement We seek to be their valued and trusted partner in the Corporate Values of the Fujitsu Way, all our ideas and actions originate from a customer-centric
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More information(ii) Methodologies employed for evaluating the inventive step
1. Inventive Step (i) The definition of a person skilled in the art A person skilled in the art to which the invention pertains (referred to as a person skilled in the art ) refers to a hypothetical person
More informationNOTICE OF THE 113TH ORDINARY GENERAL MEETING OF SHAREHOLDERS
This document has been translated from the Japanese original for the convenience of non-japanese shareholders. In the event of any discrepancy between this translation and the Japanese original, the original
More informationA gender perspective on the 2005 Census of Korea (R.O.K) Focusing on Economic Activity, and Living Expense of the Aged.
GLOBAL FORUM ON GENDER STATISTICS ESA/STAT/AC.168/28 26-28 January 29 English only Accra, Ghana A gender perspective on the 25 Census of Korea (R.O.K) Focusing on Economic Activity, and Living Expense
More informationRecommendations on Formulating a Grand Design for Asian Pharmaceutical and Medical Device Regulatory Harmonization
Recommendations on Formulating a Grand Design for Asian Pharmaceutical and Medical Device Regulatory Harmonization A Four-Wheel Drive Approach to Promoting Regulatory Harmonization in Asia Executive Committee
More informationPharmaceutical Products and Services
Pharmaceutical Products and Services Johnson Matthey (JM) combines specialist expertise and a 200-year heritage, to deliver a collaborative service offering focused on strengthening your products to ensure
More informationNote: The original disclosure in Japanese was released on November 19, 2018 at 5:00pm (JST)
(NOTE) This document has been translated from Japanese original for reference purposes only. In the event of any discrepancy between this translated document and Japanese original, the original shall prevail.
More informationAustralian/New Zealand Standard
AS/NZS 4114.2 Australian/New Zealand Standard Spray painting booths, designated spray painting areas and paint mixing rooms Part 2: Installation and maintenance This Joint Australian/New Zealand Standard
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationNOTICE OF THE 71ST ANNUAL GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the
More informationEU, USA and Japan (II) Reports from Regulators on Exchange Assignments
EU, USA and Japan (II) Reports from Regulators on Exchange Assignments Yoshikazu Hayashi MHLW/PMDA Liaison at EMA PMDA 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Disclaimer The views
More information4 The Examination and Implementation of Use Inventions in Major Countries
4 The Examination and Implementation of Use Inventions in Major Countries Major patent offices have not conformed to each other in terms of the interpretation and implementation of special claims relating
More informationFrom API to Formulated Product
From API to Formulated Product Jean-Marie Geoffroy, PhD Director, Product Development Takeda Global Research & Development 675 N Field Drive Lake Forest, IL 60045 jean-marie.geoffroy@tgrd.com Acknowledgments
More informationNOTICE OF THE 42ND ORDINARY GENERAL MEETING OF SHAREHOLDERS
Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the
More informationEuropean Commission Health and Consumers Directorate General, Brussels
PDA EUROPE Adalbertstr, 9 16548 Glienicke/Berlin Germany Tel: +49 33056 2377-0 or -10 Fax: +49 33056 2377-77 or -15 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
More informationTechnology Transfer as the Process of Pharmaceutical Quality System: Modelling Technology Transfer as a Process Strategy
Journal of Pharmacy and Pharmacology 5 (2017) 299-313 doi: 10.17265/2328-2150/2017.06.002 D DAVID PUBLISHING Technology Transfer as the Process of Pharmaceutical Quality System: Modelling Technology Transfer
More informationCSR Initiatives. Safety and Cleanliness of Products and Services
es CSR Initiativ BANDAI NAMCO Group focuses its initiatives on the underlying corporate concept Fun for the future! by promoting the corporate social responsibility (CSR) activities to provide Dreams,
More information